The promising in vitro and in vivo activity of HSP90 inhibitors in preclinical models of various cancer types has led to a large number of clinical trials testing the efficacy of these drugs as monotherapy and in combination with other targeted therapies in hematologic and solid-organ malignancies [5]; (https://clinicaltrials.gov). This evidence concerns the gene HSP90AA1 and cancer.